


AMENDMENTS TO AND LISTING OF CLAIMS


1. (Currently amended) A compound of formula I




wherein

R₁ is C₁₋₆-alkyl optionally substituted by OH, C₁₋₂-alkoxy or 1-to-6 fluorine atoms; C₂₋₆-alkenyl; or C₂₋₆-alkynyl;


R₂ is a radical of formula a[[.]] or b or c



a



b



c

wherein

R₆ is C₁₋₁₂-alkyl optionally substituted by halogen, by an optionally-substituted cycloalkyl, by an optionally-substituted phenyl, by an optionally-substituted heteroaryl, or by an optionally-substituted heterocyclic residue, wherein the C₁₋₁₂-alkyl optionally is interrupted by one or more O or C=O; and wherein the phenyl, heteroaryl, cycloalkyl, and/or heterocyclic residue may be substituted by 1-to-5 substituents independently selected from hydroxy; halogen; C₁₋₄-alkyl; C₁₋₄-alkyl substituted by 1-to-5 fluorine atoms; C₁₋₄-alkoxy; C₁₋₄-alkoxy substituted by 1-to-5 fluorine atoms; cyano; phenyl; and phenyl substituted by 1-to-5 substituents independently selected from hydroxy, halogen, C₁₋₄-alkyl, C₁₋₄-alkoxy, and cyano;

R₇ is H, optionally-substituted phenyl, optionally-substituted heteroaryl, wherein the phenyl and/or heteroaryl, independently, may be substituted by 1-to-5 substituents independently selected from

hydroxy; halogen; C₁₋₄-alkyl; C₁₋₄-alkyl substituted by 1-to-5 fluorine atoms; C₁₋₄-alkoxy; C₁₋₄-alkoxy substituted by 1-to-5 fluorine atoms; and cyano;

X is O, C=O, S or a bond;

Z is N or O;


R₃ is -A-B-COOH, wherein each of A and B, independently, is a bond, C=O or CDE, wherein each of D and E, independently, is H, halogen, C₁₋₃-alkyl[[.]] or OH; with the proviso that A and B are not both C=O; and each of R₄ and R₅, independently, is H, C₁₋₄-alkyl optionally substituted by 1, 2 or 3 halogen atoms, or acyl, wherein acyl is a residue W-CO, wherein W is C₁₋₆-alkyl, C₃₋₆-cycloalkyl, phenyl or phenylC₁₋₄-alkyl;

with the proviso that when R₄ is H, R₅ is H, R₃ is COOH, R₂ is a radical of formula a and R₇ is H, and either i) either R₁ is CH₂OH and XR₆ is a radical an unsubstituted C₁₋₁₂-alkyl not substituted, then XR₆ that is not para to (CH₂)₂-CR₁R₃(NR₄R₅); or

ii) or R₁ is CH₃ and XR₆ is a radical an unsubstituted OC₁₋₁₂-alkyl non substituted, then XR₆ that is not meta to (CH₂)₂-CR₁R₃(NR₄R₅);

where heteroaryl is pyridyl, pyrimidinyl, pyrazinyl, furyl, oxazolyl, isoxazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl or pyrazolyl; cycloalkyl is C₃₋₆-cycloalkyl; and a heterocyclic residue is tetrahydrofuryl, tetrahydropyranly, aziridinyl, piperidinyl, pyrrolidinyl or piperazinyl;
in free form or in salt form.

2. (Currently amended) A compound of formula II



wherein R₁, R₂, R₃ and R₅ are as defined in Claim 1, and R'₄ is a protecting group selected from benzyl, p-methoxybenzyl, methoxymethyl, tetrahydropyranly, trialkylsilyl, acyl where acyl is a residue W-CO wherein W is C₁₋₆-alkyl, C₃₋₆-

cycloalkyl, phenyl or phenylC₁₋₄-alkyl, tert-butoxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl and trifluoroacetyl, or a salt thereof.

3. (Currently amended) A compound according to Claim 1 which is selected from (R)-3-amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.

4. (Currently amended) A pharmaceutical composition containing comprising a compound according to Claim 1 in free form or in a pharmaceutically-acceptable salt form, together with one or more pharmaceutically-acceptable diluents or carriers therefor.


5, 6. (Canceled)

7. (Withdrawn by the Examiner) A pharmaceutical combination comprising a compound according to claim 1 in free form or in a pharmaceutically acceptable salt form and a further agent selected from immunosuppressive, immunomodulating, anti-inflammatory and chemotherapeutic agents.

8. (Canceled)

9. (Withdrawn by the Examiner) A method of treatment or prevention of allograft rejection, autoimmune disease, graft versus host disease, inflammatory diseases, myocarditis, hepatitis, ischemia/reperfusion injury, hemorrhage shock, traumatic shock, angiogenesis, Alzheimer's disease, cancer, infectious diseases or senile dementia, comprising administering to said subject a therapeutically effective amount of a compound according to claim 1 in free form or in a pharmaceutically acceptable salt form.

10. (Withdrawn by the Examiner) The method of claim 9 wherein the compound is of formula II




wherein R_1 , R_2 , R_3 and R_5 are as defined in claim 1, and R'_4 is a protecting group, or a salt thereof.

11. (Withdrawn by the Examiner) The method of claim 9 wherein the compound is selected from (R)-3-Amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-Amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-Amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.

12, 13. (Canceled)

14. (Withdrawn by the Examiner) A method of treatment or prevention of allograft rejection, autoimmune disease, graft versus host disease, inflammatory diseases, myocarditis, hepatitis, ischemia/reperfusion injury, hemorrhage shock, traumatic shock, angiogenesis, Alzheimer's disease, cancer, infectious diseases or senile dementia, comprising administering to said subject a therapeutically effective amount of a composition according to claim 4.


15. (Withdrawn by the Examiner) The composition of claim 14 wherein the compound is of formula II



wherein R_1 , R_2 , R_3 and R_5 are as defined are as defined in claim 1, and R'_4 is a protection group, or a salt thereof.

16. (Withdrawn by the Examiner) The method of claim 14 wherein the compound is selected from (R)-3-Amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-Amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-Amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.

17. (Withdrawn by the Examiner) The pharmaceutical combination of claim 7 wherein the compound is of formula II



wherein R₁, R₂, R₃ and R₅ are as defined are as defined in claim 1, and R'₄ is a protecting group, or a salt thereof.

18. (Withdrawn by the Examiner) The pharmaceutical combination of claim 7 wherein the compound is selected from (R)-3-Amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-Amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-Amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.